文献速递肝病

非酒精性脂肪性肝病的进展与长期结局:一项全国性配对肝活检队列研究

Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
PubMed 文献 · J Hepatol · 2023-08-19

该研究纳入瑞典718例经活检确诊的非肝硬化非酒精性脂肪性肝病(NAFLD)成人,均有≥2次间隔>6个月的肝活检(1969-2017年)。中位间隔3.4年间30.4%患者出现组织学进展,进展组发生终末期肝病(ESLD)的风险显著高于稳定/消退组(aHR 1.65,95%CI 1.17-2.32),但全因死亡率无显著差异(aHR 0.99,95%CI 0.78-1.24)。

要点

  • 配对肝活检队列中30.4%的NAFLD患者出现组织学进展,包括12.5%新发非纤维化性脂肪性肝炎、24.0%新发纤维化、5.6%进展为肝硬化。
  • NAFLD进展与ESLD发生风险显著升高相关(aHR 1.65,95%CI 1.17-2.32),进展至肝硬化时ESLD发生率最高。
  • NAFLD进展与全因死亡率无显著差异(aHR 0.99,95%CI 0.78-1.24)。

核心结论

  • 在全国性真实世界配对肝活检队列中,NAFLD组织学进展与ESLD发生率显著升高相关,但似乎未影响全因死亡率。

研究设计与样本

  • 研究纳入瑞典718例经活检确诊的非肝硬化NAFLD成人,均有≥2次间隔>6个月的肝活检(1969-2017年)。
  • 初始活检时将NAFLD分为单纯性脂肪变、非纤维化性脂肪性肝炎(NASH)或非肝硬化性纤维化。
  • NAFLD进展定义为两次活检间的组织学变化,即新发NASH、新发纤维化、纤维化进展或肝硬化。
  • 采用Cox回归估计NAFLD进展 vs 稳定/消退疾病对ESLD发生和死亡的多变量校正风险比(aHR)及95%CI。

主要发现

  • 初始活检时497例(69.2%)为单纯性脂肪变,90例(12.5%)为非纤维化性NASH,131例(18.2%)为非肝硬化性纤维化。
  • 两次活检中位间隔3.4年,30.4%(218/718)出现NAFLD进展,包括12.5%(62/497)新发非纤维化性NASH、24.0%(141/587)新发纤维化、5.6%(40/718)进展为肝硬化。
  • 与稳定/消退疾病相比,NAFLD进展与ESLD发生率显著升高相关(23.8 vs 11.4/1000人年;差值=12.4/1000人年;aHR 1.65,95%CI 1.17-2.32)。
  • 进展至肝硬化时ESLD发生率最高(与稳定/消退疾病的差值=56.3/1000人年),早期转变如从单纯性脂肪变至新发纤维化也显示显著超额风险(与稳定/消退疾病的差值=18.9/1000人年)。
  • NAFLD进展与稳定/消退疾病相比,全因死亡率似乎无差异(差值=4.7/1000人年;aHR 0.99,95%CI 0.78-1.24)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: More data are needed regarding the long-term impact of the histological progression of non-alcoholic fatty liver disease (NAFLD) on long-term outcomes, including end-stage liver disease (ESLD) and mortality. METHODS: We included Swedish adults with biopsy-confirmed non-cirrhotic NAFLD and ≥2 liver biopsies >6 months apart (1969-2017; n = 718). NAFLD was categorized at initial biopsy as simple steatosis, non-fibrotic steatohepatitis (NASH), or non-cirrhotic fibrosis. NAFLD progression was defined by histological changes between biopsies (i.e. incident NASH, incident fibrosis, fibrosis progression, cirrhosis). Using Cox regression, we estimated multivariable adjusted hazard ratios (aHRs) and 95% CIs for incident ESLD (i.e. hospitalization for decompensated cirrhosis, hepatocellular carcinoma or liver transplantation) and mortality, according to NAFLD progression vs. stable/regressed disease. RESULTS: At initial biopsy, 497 patients (69.2%) had simple steatosis, 90 (12.5%) had non-fibrotic NASH, and 131 (18.2%) had non-cirrhotic fibrosis. Over a median of 3.4 years between biopsies, 30.4% (218/718) experienced NAFLD progression, including 12.5% (62/497) with incident non-fibrotic NASH, 24.0% (141/587) with incident fibrosis, and 5.6% (40/718) with cirrhosis. Compared to stable/regressed disease, NAFLD progression was associated with significantly higher rates of developing incident ESLD (23.8 vs. 11.4/1,000 person-years [PY]; difference = 12.4/1,000 PY; aHR 1.65, 95% CI 1.17-2.32). While the highest ESLD incidence occurred with progression to cirrhosis (difference vs. stable/regressed disease = 56.3/1,000 PY), significant excess risk was also found with earlier transitions, including from simple steatosis to incident fibrosis (difference vs. stable/regressed disease = 18.9/1,000 PY). In contrast, all-cause mortality rates did not appear to differ when NAFLD progression was compared to stable/regressed disease (difference = 4.7/1,000 PY; aHR 0.99, 95% CI 0.78-1.24). CONCLUSIONS: In a nationwide, real-world cohort of patients with paired NAFLD biopsies, histological disease progression contributed to significantly higher rates of developing incident ESLD, but did not appear to impact all-cause mortality. IMPACT AND IMPLICATIONS: Currently, data are scarce regarding the long-term impact of histological progression or regression of non-alcoholic fatty liver disease (NAFLD) on subsequent risk of adverse clinical outcomes, including the development of end-stage liver disease and mortality. This is particularly important because randomized-controlled trials of NAFLD therapeutics currently focus on short-term histological endpoints as presumed surrogates for those major clinical outcomes. Thus, the results from this study can help inform the optimal design of future NAFLD therapeutic trials, while also providing the necessary evidence base for public health policies focused on preventing the development and progression of NAFLD.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Simon TG, Roelstraete B, Hagström H, et al. Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study. J Hepatol. 2023. PMID: 37604268. doi:10.1016/j.jhep.2023.08.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。